$CLDX Numeric Investors LLC Purchases New Stake in Celldex Therapeutics, Inc. (CLDX)
Posted by Nathan Sinclair on Mar 14th, 2016 // No Comments
Celldex Therapeutics logoNumeric Investors LLC acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 113,400 shares of the biopharmaceutical company’s stock, valued at approximately $1,778,000. Numeric Investors LLC owned 0.11% of Celldex Therapeutics as of its most recent SEC filing.
Several other hedge funds have also recently bought and sold shares of CLDX. DekaBank Deutsche Girozentrale raised its stake in Celldex Therapeutics by 1.0% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 50,100 shares of the biopharmaceutical company’s stock valued at $808,000 after buying an additional 500 shares during the last quarter. Tocqueville Asset Management L.P. raised its stake in Celldex Therapeutics by 54.9% in the fourth quarter. Tocqueville Asset Management L.P. now owns 73,400 shares of the biopharmaceutical company’s stock valued at $1,151,000 after buying an additional 26,000 shares during the last quarter. Nationwide Fund Advisors raised its stake in Celldex Therapeutics by 22.3% in the fourth quarter. Nationwide Fund Advisors now owns 115,044 shares of the biopharmaceutical company’s stock valued at $1,804,000 after buying an additional 20,996 shares during the last quarter. California State Teachers Retirement System raised its stake in Celldex Therapeutics by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 182,509 shares of the biopharmaceutical company’s stock valued at $2,862,000 after buying an additional 2,946 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Celldex Therapeutics by 5.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 257,436 shares of the biopharmaceutical company’s stock valued at $4,037,000 after buying an additional 13,652 shares during the last quarter.
Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded up 0.718% during trading on Monday, reaching $3.505. 3,174,040 shares of the company’s stock were exchanged. The stock’s market cap is $345.95 million. Celldex Therapeutics, Inc. has a 52-week low of $3.42 and a 52-week high of $32.82. The stock’s 50 day moving average price is $7.19 and its 200-day moving average price is $12.39.
Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Thursday, February 25th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.02. The business earned $1.80 million during the quarter, compared to the consensus estimate of $0.80 million. During the same period in the prior year, the firm earned ($0.36) EPS. The business’s revenue for the quarter was up 21.1% on a year-over-year basis. On average, equities research analysts forecast that Celldex Therapeutics, Inc. will post ($1.33) EPS for the current year.
Several research firms have recently weighed in on CLDX. Brean Capital reaffirmed a “buy” rating and set a $24.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, March 8th. Roth Capital began coverage on shares of Celldex Therapeutics in a report on Tuesday, November 24th. They set a $39.00 price objective for the company. Leerink Partner lowered shares of Celldex Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, March 7th. Leerink Swann lowered shares of Celldex Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $30.00 to $4.00 in a report on Monday, March 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $24.00 price objective on shares of Celldex Therapeutics in a report on Thursday, February 25th. Seven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $20.00.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related
Posted by Nathan Sinclair on Mar 14th, 2016 // No Comments
Celldex Therapeutics logoNumeric Investors LLC acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 113,400 shares of the biopharmaceutical company’s stock, valued at approximately $1,778,000. Numeric Investors LLC owned 0.11% of Celldex Therapeutics as of its most recent SEC filing.
Several other hedge funds have also recently bought and sold shares of CLDX. DekaBank Deutsche Girozentrale raised its stake in Celldex Therapeutics by 1.0% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 50,100 shares of the biopharmaceutical company’s stock valued at $808,000 after buying an additional 500 shares during the last quarter. Tocqueville Asset Management L.P. raised its stake in Celldex Therapeutics by 54.9% in the fourth quarter. Tocqueville Asset Management L.P. now owns 73,400 shares of the biopharmaceutical company’s stock valued at $1,151,000 after buying an additional 26,000 shares during the last quarter. Nationwide Fund Advisors raised its stake in Celldex Therapeutics by 22.3% in the fourth quarter. Nationwide Fund Advisors now owns 115,044 shares of the biopharmaceutical company’s stock valued at $1,804,000 after buying an additional 20,996 shares during the last quarter. California State Teachers Retirement System raised its stake in Celldex Therapeutics by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 182,509 shares of the biopharmaceutical company’s stock valued at $2,862,000 after buying an additional 2,946 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Celldex Therapeutics by 5.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 257,436 shares of the biopharmaceutical company’s stock valued at $4,037,000 after buying an additional 13,652 shares during the last quarter.
Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded up 0.718% during trading on Monday, reaching $3.505. 3,174,040 shares of the company’s stock were exchanged. The stock’s market cap is $345.95 million. Celldex Therapeutics, Inc. has a 52-week low of $3.42 and a 52-week high of $32.82. The stock’s 50 day moving average price is $7.19 and its 200-day moving average price is $12.39.
Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Thursday, February 25th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.02. The business earned $1.80 million during the quarter, compared to the consensus estimate of $0.80 million. During the same period in the prior year, the firm earned ($0.36) EPS. The business’s revenue for the quarter was up 21.1% on a year-over-year basis. On average, equities research analysts forecast that Celldex Therapeutics, Inc. will post ($1.33) EPS for the current year.
Several research firms have recently weighed in on CLDX. Brean Capital reaffirmed a “buy” rating and set a $24.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, March 8th. Roth Capital began coverage on shares of Celldex Therapeutics in a report on Tuesday, November 24th. They set a $39.00 price objective for the company. Leerink Partner lowered shares of Celldex Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, March 7th. Leerink Swann lowered shares of Celldex Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $30.00 to $4.00 in a report on Monday, March 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $24.00 price objective on shares of Celldex Therapeutics in a report on Thursday, February 25th. Seven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $20.00.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
